Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PARETEUM CorpTEUM · Entity 144276 | Director | February 19, 2017 | February 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PARETEUM Corp
Report date February 19, 2017 · Filed February 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 451,949 |
Reported balance
After 2017-02-19 transaction · row 1
1 source rowRow 1 · 2017-02-19 · Purchase · Acquired 275,911 · Balance 451,949 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 567,186 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 225,670 · Balance 567,186 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 804,646 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 237,460 · Balance 804,646 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 439,774 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 364,872 · Balance 439,774 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 826,454 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2022 Filed Apr 14, 2022 01:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionRestricted Stock Award · Derivative | 43,846 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-008917 · rdgdoc.xml · derivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,846 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · derivative.expiration_date: The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| April 12, 2022 Filed Apr 14, 2022 01:23 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 43,846 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-008917 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F1 · price: The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| April 07, 2022 Filed Apr 12, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,713 | $21.82 | $233,757.66 |
DisclosureSEC source: 0001437749-22-008699 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,464 F1 · kind: The sale reported herein was made to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 24, 2022 Filed Mar 10, 2022 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 23,365 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-005775 · rdgdoc.xml · derivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,365 Underlying: Common Stock · 23,365 shares Expires not disclosed F2 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F2 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 24, 2022 Filed Mar 10, 2022 02:21 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 23,365 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-005775 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,177 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests on January 3, 2023. Read SEC document |
| January 07, 2022 Filed Jan 12, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 567 | $30.75 | $17,435.25 |
DisclosureSEC source: 0001437749-22-000745 · rdgdoc.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,812 F1 · kind: The sale reported herein was made by to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 07, 2022 Filed Jan 12, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,053 | $30.75 | $63,129.75 |
DisclosureSEC source: 0001437749-22-000745 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,379 F1 · kind: The sale reported herein was made by to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| January 07, 2022 Filed Jan 12, 2022 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 8,196 | $30.75 | $252,027.00 |
DisclosureSEC source: 0001437749-22-000745 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,432 F1 · kind: The sale reported herein was made by to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| December 29, 2021 Filed Dec 31, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 705 | $39.37 | $27,755.85 |
DisclosureSEC source: 0001437749-21-029531 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,628 F1 · kind: The sale reported herein was made by to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 7,000 | $50.75 | $355,250.00 |
DisclosureSEC source: 0001437749-21-027113 · rdgdoc.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,333 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of September 15, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.10 to $51.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 7,000 | $51.08 | $357,560.00 |
DisclosureSEC source: 0001437749-21-027113 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,333 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of September 15, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.40 to $51.98, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 16, 2021 Filed Nov 19, 2021 01:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 7,000 | $51.39 | $359,730.00 |
DisclosureSEC source: 0001437749-21-027113 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · COO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,333 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of September 15, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.15 to $51.56, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 25, 2021 Filed Oct 28, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,371 | $44.62 | $105,794.02 |
DisclosureSEC source: 0001437749-21-024425 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,333 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 14, 2021 Filed Oct 19, 2021 00:30 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,221 | $39.97 | $48,803.37 |
DisclosureSEC source: 0001437749-21-023856 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,704 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 28, 2021 Filed Oct 1, 2021 00:16 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 689 | $43.12 | $29,709.68 |
DisclosureSEC source: 0001437749-21-022967 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,925 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 12,000 | $45.12 | $541,440.00 |
DisclosureSEC source: 0001437749-21-020556 · rdgdoc.xml · nonDerivative · entry 4 DE GREEF RODERICK · CIK 0001241181 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,614 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 20, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44 to $45.97, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,239 | $44.64 | $457,068.96 |
DisclosureSEC source: 0001437749-21-020556 · rdgdoc.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,614 F4 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 12,000 | $44.75 | $537,000.00 |
DisclosureSEC source: 0001437749-21-020556 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,853 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 20, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.48 to $45.26, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 17, 2021 Filed Aug 20, 2021 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 12,000 | $44.81 | $537,720.00 |
DisclosureSEC source: 0001437749-21-020556 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,853 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 20, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.26 to $45.68, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 29, 2021 Filed Jul 2, 2021 00:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 685 | $43.75 | $29,968.75 |
DisclosureSEC source: 0001437749-21-016266 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,853 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 5,000 | $33.69 | $168,450.00 |
DisclosureSEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 8 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,538 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.48 to $34.20, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 14, 2021 Filed Apr 16, 2021 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 5,000 | $33.83 | $169,150.00 |
DisclosureSEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 7 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,538 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.62 to $34.63, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,959 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-009069 · rdgdoc.xml · derivative · entry 11 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,959 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 960 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001437749-21-009069 · rdgdoc.xml · derivative · entry 10 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,959 Underlying: Common Stock · 960 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001437749-21-009069 · rdgdoc.xml · derivative · entry 9 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On May 3, 2016, the reporting person was granted an option to purchase 234,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 5,959 | $35.08 | $209,041.72 |
DisclosureSEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 6 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,538 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.55 to $35.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 5,959 | $1.64 | $9,772.76 |
DisclosureSEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 5 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 960 | $35.08 | $33,676.80 |
DisclosureSEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 4 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,538 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.55 to $35.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 960 | $1.64 | $1,574.40 |
DisclosureSEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,000 | $35.08 | $140,320.00 |
DisclosureSEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,538 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.55 to $35.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 01:43 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 4,000 | $1.81 | $7,240.00 |
DisclosureSEC source: 0001437749-21-009069 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2021 Filed Apr 15, 2021 01:37 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 3,222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-008949 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,538 F1 · price: The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests in six (6) months. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 3,855 | $36.53 | $140,823.15 |
DisclosureSEC source: 0001437749-21-008329 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,316 F2 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 01:31 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 9,932 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-008329 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus. F1 · price: The reporting person was granted restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") on March 25, 2020. In accordance with the terms of the grant, the restricted stock vested as to 75.5% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. The grant was made in lieu of such reporting person receiving a 2020 cash performance bonus. Read SEC document |
| March 26, 2021 Filed Mar 31, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 2,893 | $35.01 | $101,283.93 |
DisclosureSEC source: 0001437749-21-007718 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,239 F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001437749-21-007228 · rdgdoc.xml · derivative · entry 9 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 10,000 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On May 3, 2016, the reporting person was granted an option to purchase 234,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $37.71 | $377,100.00 |
DisclosureSEC source: 0001437749-21-007228 · rdgdoc.xml · nonDerivative · entry 6 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,132 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.91 to $38.65, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.81 | $18,100.00 |
DisclosureSEC source: 0001437749-21-007228 · rdgdoc.xml · nonDerivative · entry 5 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001437749-21-007228 · rdgdoc.xml · derivative · entry 8 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 10,000 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On May 3, 2016, the reporting person was granted an option to purchase 234,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $40.18 | $401,800.00 |
DisclosureSEC source: 0001437749-21-007228 · rdgdoc.xml · nonDerivative · entry 4 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,132 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.00 to $41.95, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.81 | $18,100.00 |
DisclosureSEC source: 0001437749-21-007228 · rdgdoc.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2021 Filed Mar 26, 2021 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001437749-21-007228 · rdgdoc.xml · derivative · entry 7 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 10,000 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On May 3, 2016, the reporting person was granted an option to purchase 234,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. Read SEC document |
| March 23, 2021 Filed Mar 26, 2021 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 10,000 | $41.83 | $418,300.00 |
DisclosureSEC source: 0001437749-21-007228 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,132 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 17, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.3 to $46.63, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 23, 2021 Filed Mar 26, 2021 00:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 10,000 | $1.81 | $18,100.00 |
DisclosureSEC source: 0001437749-21-007228 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,509 | $40.76 | $183,786.84 |
DisclosureSEC source: 0001437749-21-003512 · rdgdoc.xml · nonDerivative · entry 5 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,132 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 18, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,520 | $40.67 | $183,828.40 |
DisclosureSEC source: 0001437749-21-003512 · rdgdoc.xml · nonDerivative · entry 4 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,641 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 4,424 | $41.55 | $183,817.20 |
DisclosureSEC source: 0001437749-21-003512 · rdgdoc.xml · nonDerivative · entry 3 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,161 F3 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantRestricted Stock Award · Derivative | 4,740 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-003512 · rdgdoc.xml · derivative · entry 6 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,740 Underlying: Common Stock · 4,740 shares Expires not disclosed F4 · shares: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period. Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Exercise / conversionCommon Stock | 31,552 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003512 · rdgdoc.xml · nonDerivative · entry 2 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). F2 · price: The reporting person was granted restricted stock pursuant to the Plan on February 25, 2019. In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2019 through December 31, 2020 as compared to the total shareholder return of 20 of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| February 08, 2021 Filed Feb 20, 2021 01:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 4,740 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-003512 · rdgdoc.xml · nonDerivative · entry 1 DE GREEF RODERICK · CIK 0001241181 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,033 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2021 compensation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.